Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $19.27M (cash outflow) fell 28.3% year over year, behind the -21.5% change in trailing-twelve-month net income. Sequentially, it fell 4.5% from the prior quarter. Over 3 fiscal years it compounded at -9.9% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$62.42M (-31.1%) for the fiscal year ending Dec 2026, a slowdown from the -18.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.27M-4.5% QoQ
- Last fiscal yearDec 2025
- -$90.6M-18.5% YoY
- LTMMar 2026
- -$83.01M-21.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -28.3% | -57.8% | -29.5 pp |
| 1 year | -18.5% | -31.1% | -12.6 pp |
| 3-year CAGR | -9.9% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (90.6M) USD
- Year-over-year change
- +18.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (90.6M) | +18.5% |
| FY2024 | 2024-12-31 | (111.13M) | +10.4% |
| FY2023 | 2023-12-31 | (124.08M) | -0.3% |
| FY2022 | 2022-12-31 | (123.67M) | -70.1% |
| FY2021 | 2021-12-31 | (72.72M) | — |
Net Income vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 net income of $83.01M is the 4th largest of the 11 companies compared; the peer median is $76.56M.
- Its year-over-year change of -21.5% is the 9th highest of 11, against a peer median of -10.9%.
- Net income amounts to 36891.1% of revenue for TNYA, versus a peer median of 460.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $133.22M | -9.9% | +14.2% | 1189.1% | |
| LTM Mar 2026 | $116.64M | +37.7% | +37.1% | 319.6% | |
| LTM Mar 2026 | $97.59M | +25.7% | +50.6% | 4840.8% | |
| LTM Mar 2026 | $83.01M | -21.5% | -9.9% | 36891.1% | |
| LTM Mar 2026 | $81.74M | -14.2% | -13.0% | 589.8% | |
| LTM Mar 2026 | $77.8M | -39.1% | -4.8% | 465.3% | |
| LTM Mar 2026 | $75.32M | -6.4% | -12.0% | 266.9% | |
| LTM Mar 2026 | $66.14M | +249.7% | — | 454.9% | |
| LTM Mar 2026 | $61.98M | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $57.09M | -16.9% | +0.6% | — | |
| LTM Mar 2026 | $54.44M | -11.9% | +3.5% | — | |
| Peer median (excluding TNYA) | $76.56M | -10.9% | +0.6% | 460.1% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Depreciation & Amortization | 2.96M | 6.47M | 8.69M | 8.47M | 8.85M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.95M | 11.47M | 15.31M | 16.5M | 13.05M |
| Change in Working Capital | 4.74M | (849K) | (5.65M) | (7.93M) | (2.46M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 8.6M | 1.66M | (3.28M) | (581K) | (1.43M) |
| Other Working Capital | (3.86M) | (2.51M) | (2.37M) | (7.35M) | (1.03M) |
| Other Non-Cash Items | 1.26M | 2.16M | 3.66M | 3.59M | 2.9M |
| Operating Cash Flow | (60.81M) | (104.42M) | (102.07M) | (90.5M) | (68.26M) |
| Capital Expenditures | (25.12M) | (20.63M) | (1.24M) | (1.03M) | (618K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (213.44M) | (140.48M) | (56.64M) | (87.07M) | 0 |
| Sales of Investments | 0 | 244.75M | 106.62M | 89.21M | 56.7M |
| Other Investing Activities | 0 | 8K | (25K) | 17K | 0 |
| Investing Cash Flow | (238.56M) | 83.65M | 48.72M | 1.13M | 56.08M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 188.54M | 77.39M | 3.87M | 46.76M | 108.41M |
| Common Stock Repurchased | (13K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 461K | 380K | 181K | 987K | 0 |
| Financing Cash Flow | 208.97M | 77.77M | 4.05M | 47.75M | 108.41M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (90.41M) | 57M | (49.31M) | (41.62M) | 96.22M |
| Free Cash Flow | (85.93M) | (125.05M) | (103.31M) | (91.53M) | (68.88M) |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.